CFO
DNLI icon

CVA Family Office’s Denali Therapeutics DNLI Stock Holding History

CVA Family Office’s Portfolio DNLI Stock Details DNLI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$2.21K Buy
86
+23
+37% +$473 ﹤0.01% 1502
2026
Q1 		$1.21K Buy
+63
New +$1.25K ﹤0.01% 1621
2025
Q1 		– Sell
-30
Closed -$611 – 1415
2024
Q4 		$611 Hold
30
– – ﹤0.01% 1184
2024
Q3 		$874 Hold
30
– – ﹤0.01% 1091
2024
Q2 		$697 Buy
+30
New +$576 ﹤0.01% 1122

Other funds holding DNLI

T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Temasek Holdings
Temasek Holdings Singapore $37.3B AUM 12.6% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

CVA Family Office's DNLI Position: Q2 2026 in Review

CVA Family Office increased its Denali Therapeutics (DNLI) stake by 37% in Q2 2026, buying an estimated $473 and bringing the position to 86 shares worth $2.21K. The position accounts for ﹤0.01% of the portfolio, ranked #1502.

CVA Family Office first reported a position in DNLI in Q2 2024 and has held it in 5 quarters since. 292 funds tracked by Wall St. Rank hold DNLI as of Q2 2026.

  • CVA Family Office held 86 shares of Denali Therapeutics worth $2.21K as of Q2 2026.
  • CVA Family Office bought 23 Denali Therapeutics shares in Q2 2026, an estimated $473.
  • Denali Therapeutics made up ﹤0.01% of CVA Family Office's portfolio in Q2 2026, its #1502 holding.
  • CVA Family Office first reported a position in Denali Therapeutics in Q2 2024 and has held it in 5 quarters since.
  • 292 funds tracked by Wall St. Rank held Denali Therapeutics as of Q2 2026.

Based on CVA Family Office's 13F filing for Q2 2026, filed 7 Aug 2026.